Peer-reviewed article
The 2026 measles resurgence in Bangladesh and its public health implications
Md. Kamrujjaman, Faizunnesa Khondaker, Alvi Ahmed Sarker, Nuzhat Nuari Khan Rivu ·
Summary
Written by AI, not yet AICS's view · claude-sonnet-5-5This situation analysis looks at the measles outbreak in Bangladesh that began in March 2026. It draws on 19 sources, including WHO, UNICEF and national health bulletins, reviewed over five days in April 2026. The outbreak is concentrated in a few areas and mostly affects young children who were never vaccinated. The authors conclude it comes from built-up gaps in immunity, not from vaccine failure, and they call for targeted vaccination, vitamin A supplementation, stronger paediatric care and real-time surveillance.
Key points
- As of 15 April 2026, the DGHS reported 19,161 suspected cases, 2,973 confirmed cases, 166 suspected deaths and 32 confirmed deaths since 15 March.
- A WHO update dated 15 April reported 58 affected districts.
- Dhaka and Rajshahi together accounted for 62.7% of suspected cases.
- Children under five made up 81% of cases, including 34% infants under nine months; 72% of cases were zero-dose and 16% partially vaccinated.
- Valid MR1 coverage fell from 88.6% (2019) to 86.1% (2023), and valid MR2 coverage fell from 89.1% to 80.7%.
Limitations
This is a rapid review of aggregated, publicly available data (19 of 46 records screened) over five days, so figures may be incomplete or change as the outbreak continues. It does not test any intervention, and the abstract does not show how the causes were established beyond the coverage trends.
Abstract
Abstract Background Measles has resurged globally in the post-pandemic period as routine immunisation recovery remains below the two-dose threshold required to interrupt transmission. Bangladesh, previously nearing measles–rubella elimination, entered 2026 with widening coverage gaps, depleted vaccine stocks, and increasing numbers of missed children. We conducted a situation analysis to assess the scale, concentration, and programmatic implications of the outbreak. Methods We performed a rapid mixed-evidence review from 11–15 April 2026 using data from WHO, UNICEF, DGHS bulletins, PubMed/MEDLINE, ReliefWeb, SEARO updates, and Bangla-language media. Of 46 records screened, 19 were included. Analysis was based on aggregated, publicly available surveillance and programme data. Findings The DGHS measles press release dated 15 April 2026 reported cumulative totals since 15 March of 19,161 suspected cases, 2,973 confirmed cases, 166 suspected deaths, and 32 confirmed deaths; a WHO update dated 15 April reported 58 affected districts. The cumulative suspected-case burden was spatially concentrated: Dhaka and Rajshahi together accounted for 62.7% of suspected cases, and the division-level HHI was 0.255. Children under five comprised 81% of cases, including 34% infants under nine months. Vaccination status showed 72% zero-dose and 16% partially vaccinated cases. Valid MR1 coverage declined from 88.6% in 2019 to 86.1% in 2023, while valid MR2 coverage declined from 89.1% to 80.7%, indicating a widening immunity gap. Interpretation The resurgence reflects accumulated immunity gaps rather than vaccine failure, driven by subnational inequities and programme disruption. Urgent priorities include targeted vaccination campaigns, restoration of vitamin A supplementation, strengthening paediatric care capacity, and integrating real-time surveillance into outbreak response.